Powered by

CytoDyn Files For FDA's Priority Review Designation For BLA For Leronlimab - Qui…

Jun 01, 2020 - Nasdaq

(RTTNews) - Biotechnology company CytoDyn Inc. (CYDY.OB) announced Monday that it has filed with the U.S. Food and Drug Administration (FDA) a request seeking Priority Review designation for its Biologics License Application (BLA) for leronlimab as a combination therapy for HIV indication. The Company filed its BLA for Leronlimab as a Combination Therapy for Highly Treatment Experienced HIV Patients with the FDA on April 27, 2020, and submitted additional FDA requested clinical datasets on May ...